Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies

被引：12

作者：

Bhamidipati, Deepak ^{[1
]}

Subbiah, Vivek ^{[2
,3
,4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX 77030 USA

来源：

TRENDS IN CANCER | 2023年 / 9卷 / 03期

基金：

美国国家卫生研究院;

关键词：

TUMOR MUTATIONAL BURDEN; MISMATCH REPAIR DEFICIENCY; POSITIVE SOLID TUMORS; PAN-CANCER EFFICACY; OPEN-LABEL; COLORECTAL-CANCER; METASTATIC CHOLANGIOCARCINOMA; GENE FUSIONS; SINGLE-ARM; PHASE; 1/2;

D O I：

10.1016/j.trecan.2022.11.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastrointestinal (GI) malignancies encompass a broad range of tumors with lim-ited treatment options, particularly for advanced disease. With the development and implementation of next-generation sequencing (NGS) in routine practice, molecular-targeting therapies have been increasingly incorporated into the treat-ment paradigm for various cancers. Several drugs have achieved tissue-agnostic regulatory approvals, which offer promising biomarker-driven therapy options for patients with advanced GI malignancies. In this review, we focus on the clin-ical evidence for recent drug approvals for neurotrophic tyrosine receptor kinase (NTRK) fusion, microsatellite instability-high (MSI-H) phenotype, tumor mutation burden-high (TMB-H), BRAF V600E, and rearranged during transfection (RET), in the context of GI malignancies. We also highlight the future landscape of tissue-agnostic targets, such as human epidermal growth factor receptor 2 (HER2)/neu, fibroblast growth factor receptor (FGFR), and neuregulin (NRG)-1.

引用

页码：237 / 249

页数：13

共 83 条

[1] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[2] Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors [J].

Adashek, Jacob J. ;

Menta, Arjun K. ;

Reddy, Neha K. ;

Desai, Aakash P. ;

Roszik, Jason ;

Subbiah, Vivek .

MOLECULAR CANCER THERAPEUTICS, 2022, 21 (06) :871-878

[3] Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature [J].

Allen, Michael J. ;

Zhang, Amy ;

Bavi, Prashant ;

Kim, Jaesung C. ;

Jang, Gun Ho ;

Kelly, Deirdre ;

Perera, Sheron ;

Denroche, Rob E. ;

Notta, Faiyaz ;

Wilson, Julie M. ;

Dodd, Anna ;

Ramotar, Stephanie ;

Hutchinson, Shawn ;

Fischer, Sandra E. ;

Grant, Robert C. ;

Gallinger, Steven ;

Knox, Jennifer J. ;

O'Kane, Grainne M. .

JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (03) :158-165

[4] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. [J].

Andre, Thierry ;

Berton, Dominique ;

Curigliano, Giuseppe ;

Ellard, Susan ;

Trigo Perez, Jose Manuel ;

Arkenau, Hendrik-Tobias ;

Abdeddaim, Cyril ;

Moreno, Victor ;

Guo, Wei ;

Im, Ellie ;

Starling, Naureen .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[5] The oncogenic roles of NTRK fusions and methods of molecular diagnosis [J].

Aref-Eshghi, Erfan ;

Lin, Fumin ;

Li, Marilyn M. ;

Zhong, Yiming .

CANCER GENETICS, 2021, 258 :110-119

[6] Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry [J].

Arnold, A. ;

Daum, S. ;

von Winterfeld, M. ;

Berg, E. ;

Hummel, M. ;

Horst, D. ;

Rau, B. ;

Stein, U. ;

Treese, C. .

PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (11)

[7]

Bang YJ, 2010, LANCET, V376, P1302

[8] MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories [J].

Bocciarelli, Claire ;

Caumont, Charline ;

Samaison, Laura ;

Cariou, Melanie ;

Aline-Fardin, Aude ;

Doucet, Laurent ;

Roudie, Jean ;

Terris, Benoit ;

Merlio, Jean-Philippe ;

Marcorelles, Pascale ;

Cappellen, David ;

Uguen, Arnaud .

HUMAN PATHOLOGY, 2021, 114 :99-109

[9] Landscape of Microsatellite Instability Across 39 Cancer Types [J].

Bonneville, Russell ;

Krook, Melanie A. ;

Kautto, Esko A. ;

Miya, Jharna ;

Wing, Michele R. ;

Chen, Hui-Zi ;

Reeser, Julie W. ;

Yu, Lianbo ;

Roychowdhury, Sameek .

JCO PRECISION ONCOLOGY, 2017, 1 :1-15

[10] Mismatch repair deficiency testing in clinical practice [J].

Buza, Natalia ;

Ziai, James ;

Hui, Pei .

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (05) :591-604

← 1 2 3 4 5 6 7 8 9 →